Hirobriz Breezhaler (Indacaterol)

Hirobriz Breezhaler is indicated for the maintenance treatment of airflow limitation in specific respiratory conditions.

• Chronic obstructive pulmonary disease (COPD) to reduce exacerbations and improve lung function.
• Asthma as an add‑on therapy for patients whose disease is not adequately controlled with inhaled corticosteroids alone.
• Patients requiring once‑daily long‑acting bronchodilation for symptom control.
• Individuals who prefer a dry‑powder inhaler device for ease of use and rapid drug delivery.
• Patients with a history of frequent nighttime symptoms who benefit from sustained 24‑hour bronchodilation.
• Adults who have demonstrated stable disease and can operate the Breezhaler device correctly after training.

• Indacaterol is a selective ultra‑long‑acting β2‑adrenergic receptor agonist. After inhalation, it binds to β2 receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP. The rise in cAMP leads to relaxation of smooth‑muscle fibers, widening the bronchi and reducing airway resistance. Its high affinity and slow dissociation from the receptor provide bronchodilation that can last up to 24 hours with once‑daily dosing.

The most frequently reported adverse reactions with Hirobriz Breezhaler are generally mild, transient, and related to the respiratory tract or the inhalation technique.

Common

• Cough or throat irritation that occurs immediately after inhalation and usually resolves without treatment.
• Dry mouth, hoarseness, or mild oropharyngeal discomfort.
• Headache, often described as mild to moderate intensity.
• Nasopharyngitis or upper‑respiratory tract infection symptoms.
• Taste disturbance or a bitter after‑taste from the powder.

Serious

• Paradoxical bronchospasm leading to sudden worsening of dyspnea, which may require medical intervention.
• Cardiovascular events such as tachycardia, palpitations, hypertension, or arrhythmia, especially in patients with pre‑existing heart disease.
• Severe hypersensitivity reactions, including angioedema, urticaria, or anaphylaxis, which demand immediate emergency care.

When prescribing Hirobriz Breezhaler, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

• Assess for a history of cardiovascular disease, arrhythmias, or uncontrolled hypertension before initiating therapy.
• Use caution in patients with severe hepatic impairment, as metabolism may be altered.
• Evaluate the need for β‑blocker therapy, which can antagonize the bronchodilator effect.
• Ensure proper inhaler technique; incorrect use can reduce drug delivery and increase local irritation.
• Monitor lung function regularly to confirm therapeutic benefit and detect any decline.
• Consider alternative treatments in patients with known hypersensitivity to indacaterol or other LABAs.

Hirobriz Breezhaler may interact with other medications that affect β2‑adrenergic pathways or cardiovascular function, and clinicians should review a patient’s full medication list.

Avoid

• Non‑selective β‑blockers (e.g., propranolol) that can blunt bronchodilation.
• Monoamine oxidase inhibitors (MAOIs) used for psychiatric conditions, due to potential additive sympathomimetic effects.
• Other long‑acting β2‑agonists, as combined use may increase risk of cardiovascular adverse events.

Use with caution

• Short‑acting β2‑agonists (SABAs) for rescue therapy; monitor for cumulative tachycardia.
• Diuretics or antihypertensive agents, which may exacerbate heart rate changes.
• Theophylline, as both drugs can increase the likelihood of tremor or palpitations.